摘要
目的:探讨酪氨酸激酶抑制剂的进展与临床应用评价。方法:采用国内外专业文献进行综述与评估。结果及结论:蛋白酪氨酸激酶是一类具有酪氨酸激酶活性的蛋白质,近年来其进展迅速,上市和临床应用广泛,其抑制肿瘤细胞的损伤修复、可使肿瘤细胞分裂阻滞。成为研发高效、低毒、特异性强的新型抗癌药的重要方向。
OBJECTIVE：To discuss the progress and the clinical application evaluation of protein tyrosine kinase （PTK） inhibitors. METHODS： We reviewed and evaluated the related literatures both home and abroad. RESULTS ＆ CONCLUSION： PTKs were a kind of protein that of PTK activity, which experienced a rapid progress and were widely used in the clinic in recent years. These agents are shown to inhibit repair of impaired cancer cells and block cancer cells division. PTKs have become prominent targets for the research and development of new type anticancer drugs that of high performance, low toxicity and strong specificity.
出处
《中国医院用药评价与分析》
2006年第6期329-332,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
